Article Text

Download PDFPDF
Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis
  1. Saki Kuwabara1,
  2. Shun Tanimura1,
  3. Shogo Matsumoto2,
  4. Hiroyuki Nakamura1,
  5. Tetsuya Horita1
  1. 1 Internal Medicine, Tomakomai City Hospital, Tomakomai, Japan
  2. 2 Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan
  1. Correspondence to Dr Tetsuya Horita, Internal Medicine, Tomakomai City Hospital, Tomakomai 053-8567, Japan; thorita{at}med.hokudai.ac.jp

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Takayasu arteritis (TAK) is a form of large vessel vasculitis resulting in thickening and stenosis of the large-sized arteries, particularly the aorta and its main branches. Ulcerative colitis (UC) is a major complication of TAK, sharing some genetic background and pathogenesis.1 Serum levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), are potential biomarkers to reflect disease activity of TAK. Thus, IL-6 or TNF-α inhibitors have been used for treating refractory TAK. A randomised controlled trial suggested clinical efficacy and safety of tocilizumab in patients with refractory TAK, although the trial failed to achieve its primary endpoint.2 We here present a patient in whom tofacitinib (TOF), a Janus kinase (JAK) inhibitor, successfully induced a remission of TAK and UC resistant to both TNF-α and IL-6 inhibitors.

A 32-year-old Japanese female with a medical history of TAK and UC visited our hospital complaining of chest pain, abdominal …

View Full Text